- Home
- REPL
REPL
Replimune Group Inc.
as 03-28-2025 4:00pm EST
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WOBURN |
| Market Cap: | 851.0M | IPO Year: | 2018 |
| Target Price: | $20.00 | AVG Volume (30 days): | 682.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.96 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.92 - $17.00 | Next Earning Date: | 05-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 31.16% | Revenue Growth (next year): | N/A |
Latest Replimune Group Inc. News
REPL Breaking Stock News: Dive into REPL Ticker-Specific Updates for Smart Investing
GlobeNewswire
23 days ago
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
2 months ago
Wedbush Raises Replimune Group's Price Target to $19 From $16, Keeps Outperform Rating
GlobeNewswire
2 months ago
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
2 months ago
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TipRanks
2 months ago
Replimune price target raised to $21 from $17 at H.C. Wainwright
Zacks
2 months ago
REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA
GuruFocus.com
2 months ago
Replimune Stock Soars 16% on FDA Priority Review for Advanced Melanoma Therapy
MT Newswires
2 months ago
Replimune Group Says Lead Therapy RP1 Gains US FDA's Priority Review
Compare REPL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "REPL Replimune Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.